ORIC data suggest rinzimetostat may enhance prostate cancer sensitivity to androgen receptor inhibition

• ORIC Pharmaceuticals presented preclinical and patient-sample findings at ESMO Congress 2026 supporting rinzimetostat’s potential to enhance prostate cancer sensitivity to androgen receptor inhibition.
• Preclinical models showed rinzimetostat retained effectiveness against a mutation linked to mevrometostat resistance; no rinzimetostat-resistant cells emerged.
• Samples from treated patients with metastatic castration-resistant prostate cancer showed biological changes consistent with increased dependence on androgen receptor signaling.
• The findings support broader prostate cancer development, including the ongoing Himalayas-1 Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230315PRIMZONEFULLFEED9851715) on October 23, 2026, and is solely responsible for the information contained therein.